Quarter after quarter, analysts have been pestering management on Biogen Inc.'s conference calls about whether there would be an interim analysis for the phase III program testing its Alzheimer's disease drug aducanumab.
The use of contract research organizations (CROs) by drug developers has continued to grow at an 8 percent clip annually since 2010, reaching an estimated $86 billion in 2018, according to a new report from the Tufts Center for the Study of Drug Development (CSDD).
With shares down more than 25 percent since its $5 IPO in October, Phasebio Pharmaceuticals Inc. saw its fortunes reverse with the help of phase I data for its reversal agent, PB-2452.
The use of contract research organizations (CROs) by drug developers has continued to grow at an 8 percent clip annually since 2010, reaching an estimated $86 billion in 2018, according to a new report from the Tufts Center for the Study of Drug Development (CSDD).
After Gtx Inc.'s only clinical candidate, selective androgen receptor modulator (SARM) enobosarm, failed to improve stress urinary incontinence in postmenopausal women, the company underwent a review of strategic alternatives.
With positive phase III data in hand from its next-generation corrector, VX-659, Vertex Pharmaceuticals Inc. was in a no-lose situation as it released data from the cystic fibrosis (CF) phase III studies for its other next-generation corrector, VX-445.
SAN DIEGO – Advice for startups from pharma executives and venture capitalists abounded at the Biocom Global Life Science Partnering Conference last week.
SAN DIEGO – Advice for startups from pharma executives and venture capitalists abounded at the Biocom Global Life Science Partnering Conference last week.
Blockchain has already infiltrated the drug industry, from tracking supply chain to information management system to cryptocurrencies to pay people for their genomic sequencing.
Blockchain has already infiltrated the drug industry, from tracking supply chain to information management system to cryptocurrencies to pay people for their genomic sequencing. But now Agenus Inc. is looking to use the tracking technology to help fund drug development. The company announced plans to launch a Biotech Electronic Security Token (BEST), which will be tied to its anti-PD-1 antibody, AGEN-2034.
